EEF2K and glioblastoma: Targeting FOXM1 reduced AXL and eEF2K expression, suggesting that FOXM1-targted therapies may offer multitargeting potential due to suppressing AXL/eEF2K signaling, leading to the inhibition of cell proliferation, cell migration–invasion, and spheroid formation ability and causing apoptosis and ferroptosis induction in GBM cells (Figure 8).